Topiramate was an oral medicine used to control several types of seizures and prevent migraine. Chemically, it belonged to the sulfamate-substituted sugar group. It was first synthesized in 1979 during research into antidiabetic medicines. After researchers identified its antiseizure effects, it was developed as a treatment for epilepsy. In the United States, Topamax received its first approval in December 1996. Its approval was expanded to include migraine prevention in adults in August 2004.
BRAND NAMES
In the United States, topiramate was marketed as Topamax in immediate-release tablets and sprinkle capsules, Trokendi XR and Qudexy XR in extended-release capsules, and Eprontia as an oral solution. Brand names and availability differed between countries.
MECHANISM OF ACTION
The exact process through which topiramate controlled seizures and prevented migraine remained uncertain. Studies suggested that it reduced nerve-cell excitability in several ways: it blocked voltage-dependent sodium channels, strengthened GABA activity at certain GABA-A receptors, limited signaling through AMPA/kainate glutamate receptors, and inhibited carbonic anhydrase, especially types II and IV. These effects were thought to contribute to its clinical action.
PHARMACOKINETICS
The values below described immediate-release topiramate. Extended-release formulations had different absorption patterns.
Absorption
After an oral dose, topiramate entered the bloodstream quickly. Blood levels reached their peak about 2 hours after a 400 mg immediate-release dose. The tablets provided about 80% of the bioavailability of an oral solution, and food did not substantially change absorption.
Distribution
Approximately 15–41% of topiramate was bound to proteins in the blood, with the proportion varying by drug concentration. Across the studied range of 200–800 mg per day, blood concentrations increased roughly in proportion to the dose.
Metabolism
The body metabolized only a small portion of topiramate. Researchers identified six metabolites produced through hydroxylation, hydrolysis, and glucuronidation. Each represented less than 5% of the administered dose.
Elimination
Topiramate left the body mainly through the kidneys. About 70% of a dose appeared unchanged in the urine. Its average elimination half-life was approximately 21 hours, and blood levels generally stabilized after about 4 days in people with normal kidney function. Kidney impairment reduced its clearance.
PHARMACODYNAMICS
Topiramate’s exact action in controlling seizures and preventing migraines remained uncertain. Research suggested that it reduced activity in voltage-dependent sodium channels, strengthened some GABA-mediated signals, limited AMPA/kainate glutamate activity, and inhibited carbonic anhydrase. Together, these effects may have contributed to its therapeutic action.
ADMINISTRATION
Immediate-release topiramate was taken by mouth, with or without food. Tablets were swallowed whole because breaking them exposed a bitter taste. Sprinkle capsules were either swallowed whole or opened, with all their contents placed on about a teaspoon of soft food. The mixture was swallowed immediately without chewing and was not saved for later. Treatment was usually started and stopped gradually under a clinician’s direction.
DOSAGE AND STRENGTHS
The dosage recommendations were provided to qualified healthcare professionals to guide clinical care. Treatment was individualized based on the condition being treated, the patient’s age and body weight, kidney and liver function, coexisting medical conditions, other medications being taken, and response to therapy. The full prescribing information was reviewed before treatment began or any dose was adjusted.
Strength
25 mg
50 mg
100 mg
200 mg
DRUG INTERACTIONS
Phenytoin and carbamazepine lowered topiramate concentrations, which could require a dose adjustment.
Valproic acid taken with topiramate was associated with increased blood ammonia, encephalopathy, and low body temperature.
Hormonal contraceptives could have become less effective, even when no breakthrough bleeding occurred.
Acetazolamide and zonisamide could have increased the risks of metabolic acidosis and kidney stones.
Hydrochlorothiazide increased topiramate exposure. High-dose topiramate could have increased lithium exposure, while use with pioglitazone called for closer monitoring of diabetes control
FOOD INTERACTIONS
Guidance indicated that topiramate could be taken with or without food. Adequate fluid intake was recommended to lower the risk of kidney stones. A ketogenic or other high-fat, low-carbohydrate diet was discouraged because it could increase the risks of kidney stones and acid buildup in the blood.
Alcohol could worsen sleepiness and difficulty thinking. For some extended-release products, the instructions required avoiding alcohol for six hours before and after a dose; the exact advice depended on the product used.
CONTRAINDICATIONS
The cited U.S. tablet label listed a previous allergic reaction to topiramate or one of its tablet ingredients as a formal contraindication. Pregnancy required prompt discussion with a prescriber because the medicine could harm a developing baby. Kidney disease, previous kidney stones, metabolic acidosis, and a ketogenic diet also called for careful review. Sudden discontinuation was discouraged, particularly when topiramate was being used to control seizures.
SIDE EFFECTS
Reported side effects included tingling in the hands or feet, reduced appetite, weight loss, altered taste, nausea, diarrhea, dizziness, sleepiness, and trouble concentrating or finding words. New eye pain or vision changes, reduced sweating with fever, a severe rash or swelling, marked confusion, and suicidal thoughts were warning signs that required prompt medical attention.
OVERDOSE
An overdose could cause severe drowsiness, confusion, speech or vision problems, poor coordination, seizures, low blood pressure, coma, or severe metabolic acidosis. When an overdose was suspected, immediate contact with a poison centre or emergency service was advised, even if symptoms had not appeared. Hospital care focused on supportive treatment; hemodialysis could remove the medicine in severe cases.
TOXICITY
Metabolic acidosis could also develop during prescribed use. Possible signs included unusual tiredness, poor appetite, rapid breathing, confusion, or an irregular heartbeat. If it persisted, it could contribute to kidney stones and bone problems. The prescribing information recommended checking blood bicarbonate before treatment and periodically afterward.
